Related Experiment Video
Updated: Aug 6, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[18F]FDG PET/CT in mucosal melanoma lesional metabolic activity predicts progression
Zhi Lin1,2,3,4, Cheng Tang1,2,3,4, Tong Liu1,2,3,4
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Purpose:
This study investigates the prognostic value of [18F]FDG PET/CT-derived parameters in predicting PFS and OS in mucosal melanoma patients.
Methods:
This single-center retrospective study included 58 patients with primary mucosal melanoma who underwent [18F]FDG PET/CT imaging. PET/CT parameters (SUVmax, SUVr, WBMTV, WBTLG) were extracted from delineated lesions. Kaplan-Meier curves, ROC analysis, and univariate and multivariate Cox regression were used to assess predictive performance and identify prognostic factors for PFS and OS.
Results:
The median follow-up was 15 months (range: 1-48 months). Disease progression occurred in 47 patients (median PFS = 8.0 months, 95% CI: 7.0-11.0 months), and 30 patients died (median OS = 18.0 months, 95% CI: 15.0 months - NE). ROC analysis showed all [18F]FDG PET/CT parameters (SUVmax, SUVr, WBMTV and WBTLG) could predicted progression and mortality (all p < 0.01). The optimal cutoff value of SUVmax for predicting disease progression was 10.8 g/ml; the optimal cutoff value of WBMTV for predicting mortality was 14.1 cm3. In univariate COX analysis, SUVmax and SUVr were significantly linked to both PFS and OS (both p < 0.05), while WBMTV and WBTLG only correlated with OS (both p < 0.01). Multivariate analysis identified SUVmax as an independent predictor of PFS (HR = 1.04, p < 0.05) and WBMTV as an independent predictor of OS (HR = 2.15, p < 0.05).
Conclusion:
[18F]FDG PET/CT parameters can aid in risk stratification and treatment decisions for mucosal melanoma. SUVmax predicts disease progression, while WBMTV forecasts overall survival.
Insights
18F]FDG PET/CT parameters like SUVmax and WBMTV can predict outcomes in mucosal melanoma. SUVmax indicates disease progression risk, while WBMTV forecasts overall survival, aiding treatment decisions.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiomics
Background:
- Mucosal melanoma is a rare and aggressive cancer.
- Accurate prognostic tools are crucial for patient management and treatment stratification.
- 18F]FDG PET/CT offers quantitative imaging insights into tumor biology.
Purpose of the Study:
- To evaluate the prognostic significance of quantitative [18F]FDG PET/CT parameters in predicting progression-free survival (PFS) and overall survival (OS) in patients with mucosal melanoma.
- To identify specific PET/CT-derived metrics that can serve as independent predictors of clinical outcomes.
Main Methods:
- A retrospective analysis of 58 primary mucosal melanoma patients who underwent [18F]FDG PET/CT.
- Extraction of quantitative parameters including SUVmax, SUVr, WBMTV, and WBTLG from tumor lesions.
- Statistical analysis using Kaplan-Meier, ROC, and Cox regression models to assess predictive values for PFS and OS.
Main Results:
- All investigated [18F]FDG PET/CT parameters demonstrated significant predictive capability for both progression and mortality (p < 0.01).
- SUVmax (cutoff 10.8 g/ml) independently predicted disease progression (PFS) (HR=1.04, p<0.05).
- WBMTV (cutoff 14.1 cm3) independently predicted overall survival (OS) (HR=2.15, p<0.05).
Conclusions:
- Quantitative [18F]FDG PET/CT parameters are valuable tools for risk stratification in mucosal melanoma.
- SUVmax is a significant predictor of disease progression.
- WBMTV is a robust predictor of overall survival, informing clinical decision-making.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017